VU University Amsterdam-ko ikertzaileekin lankidetzan egindako argitalpenak (17)

2024

  1. Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without Dementia

    Neurology, Vol. 103, Núm. 7

  2. Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies

    Fluids and Barriers of the CNS, Vol. 21, Núm. 1

2023

  1. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology

    Alzheimer's and Dementia, Vol. 19, Núm. 3, pp. 807-820

  2. Multiomics profiling of human plasma and cerebrospinal fluid reveals ATN-derived networks and highlights causal links in Alzheimer's disease

    Alzheimer's and Dementia, Vol. 19, Núm. 8, pp. 3350-3364

  3. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

    Genome Medicine, Vol. 15, Núm. 1

2022

  1. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

    Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27

  2. Concerted alterations of functional connectivity and WM integrity in relationship to early amyloid deposition

    Alzheimer's and Dementia

  3. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)

    Molecular Neurodegeneration

  4. Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 14, Núm. 1

  5. Functional eigenvector centrality dynamics are related to amyloid deposition in preclinical Alzheimer’s Disease

    Alzheimer's and Dementia

  6. Functional eigenvector centrality dynamics are related to amyloid deposition in preclinical Alzheimer’s Disease

    Alzheimer's and Dementia

  7. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

    JAMA Neurology, Vol. 79, Núm. 3, pp. 228-243

2021

  1. TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels

    Alzheimer's and Dementia, Vol. 17, Núm. 10, pp. 1628-1640

2020

  1. APOE ϵ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease

    Alzheimer's Research and Therapy, Vol. 12, Núm. 1

  2. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

    Translational Psychiatry, Vol. 10, Núm. 1

  3. Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics

    Brain, Vol. 143, Núm. 12, pp. 3776-3792

2019

  1. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

    Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 5, pp. 933-938